Hosted on MSN
Myriad Genetics outlines $860M–$880M revenue target for 2026 while advancing cancer care continuum strategy
Samraat Raha, President and CEO, emphasized progress in high-growth market segments, citing "fourth quarter revenue of $210 million, coming in above the high end of the preannounced range" and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results